<DOC>
	<DOCNO>NCT01247688</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness UCBT treat patient lymphoid hematological disease see treatment decrease incidence leukemia relapse , GVHD infection . These patient type blood cell disorder hard cure . This treatment use trial know stem cell transplant . This treatment might help patient live long without disease . It use much strong dose drug radiation kill diseased cell could give without transplant . We also think healthy cell donor may help fight diseased cell leave transplant . For transplant take place , administer stem cell 'donor ' whose cell best 'match ' patient 's . In study umbilical cord source stem cell . Before transplant , two strong drug plus total body irradiation give precondition . This treatment kill blood-forming cell bone marrow . The patient get healthy stem cell . If patient disease central nervous system ( CNS ) , receive radiation head spine start conditioning . This try get disease control CNS . Radiation give child 2 yr old . Currently , many umbilical cord blood unit available public bank transplantation patient lack bone marrow donor . UCB transplant ( UCBT ) may offer several advantage adult bone marrow peripheral blood stem cell transplant , include : 1. rapid availability , 2. absence donor risk , 3. low risk transmissible infectious disease , 4. low risk acute GvHD ( Graft v . Host Disease ) The three main cause death umbilical cord blood transplantation kind disorder graft failure , infection disease relapse . In study try address three problem : To help improve engraftment add drug Fludarabine Cytoxan total body irradiation . Fludarabine strong medicine . We try decrease infection reduce leukemia relapse use fludarabine instead antithymocyte globulin ( ATG ) .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplant Children With Lymphoid Hematological Malignancies</brief_title>
	<detailed_description>After eligible criterion treatment meet suitable UCB stem donor find , patient central line place . Research Therapy : After placement central line , follow chemotherapy give admission hospital infusion umbilical cord blood stem cell : - 9 - 6 day infusion : Total Body Irradiation ( TBI ) two fraction ( `` dos '' ) per day . - 5 - 2 day infusion : Cytoxan give daily 4 day , 1 hour intravenous infusion . Mesna give per standard . Mesna drug give decrease side effect Cytoxan . It give daily intravenous infusion patient receive Cytoxan . - 4 - 2 day infusion : Fludarabine give daily 3 day 1 hour intravenous infusion . Stem cell transplant ( intravenous infusion UCB stem cell ) - define day 0 treatment . All `` numbered '' day relate infusion date . For example , Day 1 first day stem cell transplant . The following medication give help decrease side effect chemotherapy UCB infusion : Cyclosporine A ( CSA ) give start 3 day prior stem cell infusion . It give daily 2 hour every 12 hour , infusion taper GVHD present . Administration Mycophenolate mofetil ( MMF ) start day stem cell infusion complete continue daily 45 day , unless patient develops GvHD . Intravenous immunoglobulin 's ( IVIG ) give monthly GVHD therapy stop evidence patient 's body produce antibody . Study Evaluations : Various study evaluation perform trial . Follow Up : After year 1 , patient ask return clinic year consultation bone marrow test . A follow bone marrow biopsy aspirate do 1 2 year transplant . Consultations specialist similar one patient transplant .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>INCLUSION CRITERIA : Potential recipient umbilical cord blood transplantation ( i.e . HLA ( human leukocyte antigen ) match mismatch / relate unrelated ) lymphoid hematologic malignancy ( acute lymphoblastic leukemia , hodgkin/nonhodgkin lymphoma ) unlikely cure standard chemotherapy . This include patient relapsed standard chemotherapy treatment patient first remission unfavorable prognostic feature . Related Unrelated Umbilical Cord Blood Unit 01 antigen mismatch , Total Nucleated cell dose great equal 4 x 10^7/kg . Lansky/Karnofsky score great equal 60 Negative pregnancy test ( applicable ) Written informed consent and/or sign assent line patient , parent guardian . EXCLUSION CRITERIA : Patients uncontrolled infection . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior enrollment . For fungal infection patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Severe renal disease ( Creatinine &gt; x 3 normal age ) Severe hepatic disease ( direct bilirubin &gt; 3 mg/dl SGOT ( Serum glutamic oxaloacetic transaminase ) &gt; 500 ) Patient DLCO ( Diffusing Capacity Lung Carbon Monoxide ) &lt; 50 % predict FEV1 ( Forced expiratory volume ) &lt; 50 % predict , applicable Patients symptomatic cardiac failure unrelieved medical therapy evidence significant cardiac dysfunction echocardiogram ( shorten fraction &lt; 20 % ) . HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Lymphoid</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>UCB</keyword>
	<keyword>Umbilical Cord Blood Transplant</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
</DOC>